A Dark Vector Cognition product

Cover and table of contents

52K characters. Original on sec.gov ·

Cover and table of contents

The 21 tables in Cover and table of contents as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

Or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 1-11239

HCA Healthcare, Inc.

(Exact name of registrant as specified in its charter)

Delaware27-3865930
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
One Park Plaza Nashville**,** Tennessee37203
(Address of principal executive offices)(Zip Code)

(615) 344-9551

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Voting common stock, $.01 par valueHCANew York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.

Class of Common StockOutstanding at April 24, 2023
Voting common stock, $.01 par value275,189,800 shares

HCA HEALTHCARE, INC.

Form 10-Q

March 31, 2023

Page of Form 10-Q
Part I.Financial Information
Item 1.Financial Statements (Unaudited):
Condensed Consolidated Income Statements — for the quarters ended March 31, 2023 and 20223
Condensed Consolidated Comprehensive Income Statements — for the quarters ended March 31, 2023 and 20224
Condensed Consolidated Balance Sheets — March 31, 2023 and December 31, 20225
Condensed Consolidated Statements of Stockholders’ Equity (Deficit) — for the quarters ended March 31, 2023 and 20226
Condensed Consolidated Statements of Cash Flows — for the quarters ended March 31, 2023 and 20227
Notes to Condensed Consolidated Financial Statements8
Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations16
Item 3.Quantitative and Qualitative Disclosures About Market Risk26
Item 4.Controls and Procedures26
Part II.Other Information
Item 1.Legal Proceedings26
Item 1A.Risk Factors26
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds26
Item 6.Exhibits27
Signatures28

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATED INCOME STATEMENTS

FOR THE QUARTERS ENDED MARCH 31, 2023 AND 2022

Unaudited

(Dollars in millions, except per share amounts)

20232022
Revenues$15,591$14,945
Salaries and benefits7,0846,939
Supplies2,4232,321
Other operating expenses2,8942,752
Equity in losses (earnings) of affiliates18(11)
Depreciation and amortization756732
Interest expense479408
Losses (gains) on sales of facilities15(10)
13,66913,131
Income before income taxes1,9221,814
Provision for income taxes379349
Net income1,5431,465
Net income attributable to noncontrolling interests180192
Net income attributable to HCA Healthcare, Inc.$1,363$1,273
Per share data:
Basic earnings$4.92$4.21
Diluted earnings$4.85$4.14
Shares used in earnings per share calculations (in millions):
Basic276.910302.446
Diluted280.961307.374

The accompanying notes are an integral part of the condensed consolidated financial statements.

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATED COMPREHENSIVE INCOME STATEMENTS

FOR THE QUARTERS ENDED MARCH 31, 2023 AND 2022

Unaudited

(Dollars in millions)

20232022
Net income$1,543$1,465
Other comprehensive income (loss) before taxes:
Foreign currency translation18(34)
Unrealized gains (losses) on available-for-sale securities7(26)
Defined benefit plans——
Pension costs included in salaries and benefits—2
—2
Change in fair value of derivative financial instruments—4
Interest costs included in interest expense—2
—6
Other comprehensive income (loss) before taxes25(52)
Income taxes (benefits) related to other comprehensive income items5(9)
Other comprehensive income (loss)20(43)
Comprehensive income1,5631,422
Comprehensive income attributable to noncontrolling interests180192
Comprehensive income attributable to HCA Healthcare, Inc.$1,383$1,230

The accompanying notes are an integral part of the condensed consolidated financial statements.

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

Unaudited

(Dollars in millions)

March 31, 2023December 31, 2022
ASSETS
Current assets:
Cash and cash equivalents$842$908
Accounts receivable8,6578,891
Inventories2,0852,068
Other1,9571,776
13,54113,643
Property and equipment, at cost55,46354,757
Accumulated depreciation**(**29,410)(29,182)
26,05325,575
Investments of insurance subsidiaries390381
Investments in and advances to affiliates786823
Goodwill and other intangible assets9,5909,653
Right-of-use operating lease assets2,0322,065
Other319298
$52,711$52,438
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts payable$3,769$4,239
Accrued salaries1,5651,712
Other accrued expenses3,3163,581
Long-term debt due within one year2,378370
11,0289,902
Long-term debt, less debt issuance costs and discounts of $295 and $30136,47837,714
Professional liability risks1,5651,528
Right-of-use operating lease obligations1,7161,752
Income taxes and other liabilities1,6921,615
Stockholders’ equity (deficit):
Common stock $0.01 par; authorized 1,800,000,000 shares; outstanding 275,939,900 shares — 2023 and 277,378,300 shares — 202233
Accumulated other comprehensive loss**(**470)(490)
Retained deficit**(**2,028)(2,280)
Stockholders’ deficit attributable to HCA Healthcare, Inc.**(**2,495)(2,767)
Noncontrolling interests2,7272,694
232(73)
$52,711$52,438

The accompanying notes are an integral part of the condensed consolidated financial statements.

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)

FOR THE QUARTERS ENDED MARCH 31, 2023 AND 2022

Unaudited

(Dollars in millions)

Equity (Deficit) Attributable to HCA Healthcare, Inc.
CapitalAccumulatedEquity
Common Stockin ExcessOtherAttributable to
SharesParof ParComprehensiveRetainedNoncontrolling
(in millions)ValueValueLossDeficitInterestsTotal
Balances, December 31, 2021305.477$3$—$(404)$(532)$2,422$1,489
Comprehensive income (loss)(43)1,2731921,422
Repurchase of common stock(8.375)(2,101)(2,101)
Share-based benefit plans1.879(57)(57)
Cash dividends declared ($0.56 per share)(171)(171)
Distributions(171)(171)
Other(1)43
Balances, March 31, 2022298.9813—(447)(1,589)2,447414
Comprehensive income (loss)(68)1,1552241,311
Repurchase of common stock(12.230)(111)(2,571)(2,682)
Share-based benefit plans0.253118118
Cash dividends declared ($0.56 per share)(163)(163)
Distributions(162)(162)
Other(7)2922
Balances, June 30, 2022287.0043—(515)(3,168)2,538(1,142)
Comprehensive income (loss)(77)1,1342101,267
Repurchase of common stock(3.361)(113)(585)(698)
Share-based benefit plans0.261116116
Cash dividends declared ($0.56 per share)(162)(162)
Distributions(217)(217)
Other(3)6158
Balances, September 30, 2022283.9043—(592)(2,781)2,592(778)
Comprehensive income1022,0815652,748
Repurchase of common stock(6.781)(40)(1,479)(1,519)
Share-based benefit plans0.2554857105
Cash dividends declared ($0.56 per share)(159)(159)
Distributions(475)(475)
Other(8)1125
Balances, December 31, 2022277.3783—(490)(2,280)2,694(73)
Comprehensive income201,3631801,563
Repurchase of common stock**(**3.340)**(**849)**(**849)
Share-based benefit plans1.902**(**87)**(**87)
Cash dividends declared ($0.60 per share)**(**168)**(**168)
Distributions**(**187)**(**187)
Other**(**7)4033
Balances, March 31, 2023275.940$3$—$**(**470)$**(**2,028)$2,727$232

The accompanying notes are an integral part of the condensed consolidated financial statements.

HCA HEALTHCARE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE QUARTERS ENDED MARCH 31, 2023 AND 2022

Unaudited

(Dollars in millions)

20232022
Cash flows from operating activities:
Net income$1,543$1,465
Adjustments to reconcile net income to net cash provided by operating activities:
Increase (decrease) in cash from operating assets and liabilities:
Accounts receivable238(427)
Inventories and other assets**(**214)(121)
Accounts payable and accrued expenses**(**1,066)(771)
Depreciation and amortization756732
Income taxes372346
Losses (gains) on sales of facilities15(10)
Amortization of debt issuance costs and discounts97
Share-based compensation7786
Other7338
Net cash provided by operating activities1,8031,345
Cash flows from investing activities:
Purchase of property and equipment**(**1,197)(861)
Acquisition of hospitals and health care entities**(**115)(2)
Sales of hospitals and health care entities16514
Change in investments**(**13)10
Other9(6)
Net cash used in investing activities**(**1,151)(845)
Cash flows from financing activities:
Issuance of long-term debt—5,966
Net change in revolving credit facilities1,240(2,780)
Repayment of long-term debt**(**550)(66)
Distributions to noncontrolling interests**(**187)(171)
Payment of debt issuance costs**(**3)(49)
Payment of dividends**(**175)(177)
Repurchase of common stock**(**846)(2,101)
Other**(**204)(197)
Net cash (used in) provided by financing activities**(**725)425
Effect of exchange rate changes on cash and cash equivalents7(5)
Change in cash and cash equivalents**(**66)920
Cash and cash equivalents at beginning of period9081,451
Cash and cash equivalents at end of period$842$2,371
Interest payments$574$408
Income tax payments, net$7$3

The accompanying notes are an integral part of the condensed consolidated financial statements.

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 — BASIS OF PR****ESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

Reporting Entity

HCA Healthcare, Inc. is a holding company whose affiliates own and operate hospitals and related health care entities. The term “affiliates” includes direct and indirect subsidiaries of HCA Healthcare, Inc. and partnerships and joint ventures in which such subsidiaries are partners. At March 31, 2023, these affiliates owned and operated 180 hospitals, 126 freestanding surgery centers, 22 freestanding endoscopy centers and provided extensive outpatient and ancillary services. HCA Healthcare, Inc.’s facilities are located in 20 states and England. The terms “Company,” “HCA,” “we,” “our” or “us,” as used herein and unless otherwise stated or indicated by context, refer to HCA Healthcare, Inc. and its affiliates. The terms “facilities” or “hospitals” refer to entities owned and operated by affiliates of HCA and the term “employees” refers to employees of affiliates of HCA.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal and recurring nature.

The majority of our expenses are “costs of revenues” items. Costs that could be classified as general and administrative would include our corporate office costs, which were $74 million and $77 million for the quarters ended March 31, 2023 and 2022, respectively. Operating results for the quarter are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. For further information, refer to the consolidated financial statements and footnotes thereto included in our annual report on Form 10-K for the year ended December 31, 2022.

COVID-19

We believe the extent of COVID-19’s impact on our operating results and financial condition has been and could continue to be driven by many factors, most of which are beyond our control and ability to forecast. Because of these uncertainties, we cannot estimate whether or to what extent COVID-19 will impact our operations.

Revenues

Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers, managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals.

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 1 — BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (continued)

Revenues (continued)

Our revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual adjustments under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record these revenues at the estimated amounts we expect to collect. Patients treated at our hospitals for non-elective care, who have income at or below 400% of the federal poverty level, are eligible for charity care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in revenues. Our revenues by primary third-party payer classification and other (including uninsured patients) for the quarters ended March 31, 2023 and 2022 are summarized in the following table (dollars in millions):

2023Ratio2022Ratio
Medicare$2,73817.6%$2,72618.2%
Managed Medicare2,55916.42,32415.6
Medicaid7354.75793.9
Managed Medicaid9135.91,1107.4
Managed care and insurers7,62348.97,15247.9
International (managed care and insurers)3752.43562.4
Other6484.16984.6
Revenues$15,591100.0%$14,945100.0%

Managed care and insurers revenues for the quarter ended March 31, 2023 include $145 million related to resolving certain disputed claims from prior years with a commercial payer. Managed Medicaid revenues for the quarter ended March 31, 2022 include $244 million, for the period September through December 2021, related to the March 2022 Centers for Medicare & Medicaid Services ("CMS") approval of a Texas directed payment program for the program year that began September 1, 2021.

To quantify the total impact of the trends related to uninsured patient accounts, we believe it is beneficial to view total uncompensated care, which is comprised of charity care, uninsured discounts and implicit price concessions. A summary of the estimated cost of total uncompensated care for the quarters ended March 31, 2023 and 2022 follows (dollars in millions):

20232022
Patient care costs (salaries and benefits, supplies, other operating expenses and depreciation and amortization)$13,157$12,744
Cost-to-charges ratio (patient care costs as percentage of gross patient charges)10.4%11.3%
Total uncompensated care$7,991$7,005
Multiply by the cost-to-charges ratio10.4%11.3%
Estimated cost of total uncompensated care$831$792

The total uncompensated care amounts for the quarters ended March 31, 2023 and 2022 include charity care of $3.595 billion and $3.458 billion, respectively, and the related estimated costs of charity care were $374 million and $391 million, respectively.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 2 — ACQUISITIONS AND DISPOSITIONS

During the quarter ended March 31, 2023, we paid $83 million to acquire a hospital facility in Texas (effective April 1, 2023). During the quarters ended March 31, 2023 and 2022, we paid $32 million and $2 million, respectively, to acquire nonhospital health care entities. Purchase price amounts are allocated to the related assets acquired and liabilities assumed based upon their respective fair values.

During the quarter ended March 31, 2023, we received proceeds of $163 million for the sale of two hospital facilities in Louisiana. During the quarters ended March 31, 2023 and 2022, we received $2 million and $14 million, respectively, related to sales of real estate and other health care entity investments. We recognized pretax losses of $15 million and pretax gains of $10 million, respectively, for these transactions.

NOTE 3 — INCOME TAXES

Our provisions for income taxes for the quarters ended March 31, 2023 and 2022 were $379 million and $349 million, respectively, and the effective tax rates were 21.8% and 21.5%, respectively. Our provisions for income taxes included tax benefits related to settlements of employee equity awards of $74 million and $64 million for the quarters ended March 31, 2023 and 2022, respectively.

Our gross unrecognized tax benefits were $644 million, excluding accrued interest of $142 million, as of March 31, 2023 ($639 million and $129 million, respectively, as of December 31, 2022). Unrecognized tax benefits of $292 million ($278 million as of December 31, 2022) would affect the effective rate, if recognized.

At March 31, 2023, the Internal Revenue Service was conducting examinations of the Company’s 2016, 2017 and 2018 federal income tax returns and the 2019 return for one affiliated partnership. We are also subject to examination by state and foreign taxing authorities. Depending on the resolution of any federal, state and foreign tax disputes, the completion of examinations by federal, state or foreign taxing authorities, or the expiration of statutes of limitation for specific taxing jurisdictions, we believe it is reasonably possible that our liability for unrecognized tax benefits may significantly increase or decrease within the next 12 months. However, we are currently unable to estimate the range of any possible change.

NOTE 4 — EARNINGS PER SHARE

We compute basic earnings per share using the weighted average number of common shares outstanding. We compute diluted earnings per share using the weighted average number of common shares outstanding, plus the dilutive effect of outstanding equity awards, computed using the treasury stock method.

The following table sets forth the computation of basic and diluted earnings per share for the quarters ended March 31, 2023 and 2022 (dollars and shares in millions, except per share amounts):

20232022
Net income attributable to HCA Healthcare, Inc.$1,363$1,273
Weighted average common shares outstanding276.910302.446
Effect of dilutive incremental shares4.0514.928
Shares used for diluted earnings per share280.961307.374
Earnings per share:
Basic earnings$4.92$4.21
Diluted earnings$4.85$4.14

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 5 — INVESTMENTS OF INSURANCE SUBSIDIARIES

A summary of our insurance subsidiaries’ investments at March 31, 2023 and December 31, 2022 follows (dollars in millions):

March 31, 2023
Unrealized Amounts
Amortized CostGainsLossesFair Value
Debt securities$415$1$**(**32)$384
Money market funds and other102——102
$517$1$**(**32)486
Amounts classified as current assets**(**96)
Investment carrying value$390
December 31, 2022
Unrealized Amounts
Amortized CostGainsLossesFair Value
Debt securities$415$—$(38)$377
Money market funds and other96——96
$511$—$(38)473
Amounts classified as current assets(92)
Investment carrying value$381

At March 31, 2023 and December 31, 2022, the investments in debt securities of our insurance subsidiaries were classified as “available-for-sale.” Changes in unrealized gains and losses that are not credit-related are recorded as adjustments to other comprehensive income (loss).

Scheduled maturities of investments in debt securities at March 31, 2023 were as follows (dollars in millions):

Amortized CostFair Value
Due in one year or less$30$30
Due after one year through five years119114
Due after five years through ten years187168
Due after ten years7972
$415$384

The average expected maturity of the investments in debt securities at March 31, 2023 was 5.9 years, compared to the average scheduled maturity of 8.5 years. Expected and scheduled maturities may differ because the issuers of certain securities have the right to call, prepay or otherwise redeem such obligations prior to their scheduled maturity date.

NOTE 6 — ASSETS AND LIABILITIES MEASURED AT FAIR VALUE

Accounting Standards Codification 820, Fair Value Measurements and Disclosures (“ASC 820”), emphasizes fair value is a market-based measurement, and fair value measurements should be determined based on the assumptions market participants would use in pricing assets or liabilities. ASC 820 utilizes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 6 — ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (continued)

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity.

The investments of our insurance subsidiaries are generally classified within Level 1 or Level 2 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.

The following tables summarize the investments of our insurance subsidiaries measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022, aggregated by the level in the fair value hierarchy within which those measurements fall (dollars in millions):

March 31, 2023
Fair Value Measurements Using
Fair ValueQuoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Investments of insurance subsidiaries:
Debt securities$384$—$384$—
Money market funds and other102102——
Investments of insurance subsidiaries486102384—
Less amounts classified as current assets**(**96)**(**96)——
$390$6$384$—
December 31, 2022
Fair Value Measurements Using
Fair ValueQuoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
Investments of insurance subsidiaries:
Debt securities$377$—$377$—
Money market funds and other9696——
Investments of insurance subsidiaries47396377—
Less amounts classified as current assets(92)(92)——
$381$4$377$—

The estimated fair value of our long-term debt was $36.918 billion and $35.555 billion at March 31, 2023 and December 31, 2022, respectively, compared to carrying amounts, excluding debt issuance costs and discounts, aggregating $39.151 billion and $38.385 billion, respectively. The estimates of fair value are generally based on Level 2 inputs, including quoted market prices or quoted market prices for similar issues of long-term debt with the same maturities.

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 7 — LONG-TERM DEBT

A summary of long-term debt at March 31, 2023 and December 31, 2022, including related interest rates at March 31, 2023 follows (dollars in millions):

March 31, 2023December 31, 2022
Senior secured asset-based revolving credit facility (effective interest rate of 6.1%)$4,140$2,900
Senior secured revolving credit facility——
Senior secured term loan facilities (effective interest rate of 6.3%)1,3691,880
Other senior secured debt (effective interest rate of 3.9%)990953
Senior secured debt6,4995,733
Senior unsecured notes (effective interest rate of 4.9%)32,65232,652
Debt issuance costs and discounts**(**295)(301)
Total debt (average life of 9.3 years, rates averaging 5.1%)38,85638,084
Less amounts due within one year2,378370
$36,478$37,714

During January 2023, the availability under our senior secured revolving credit facility was increased by $1.500 billion to total $3.500 billion, the senior secured term loan B facility was fully retired and certain administrative updates were made to our credit agreements.

NOTE 8 — CONTINGENCIES

We operate in a highly regulated and litigious industry. As a result, various lawsuits, claims and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. We are also subject to claims and suits arising in the ordinary course of business, including claims for personal injuries or wrongful restriction of, or interference with, physicians’ staff privileges. In certain of these actions the claimants may seek punitive damages against us which may not be covered by insurance. We are also subject to claims by various taxing authorities for additional taxes and related interest and penalties. The resolution of any such lawsuits, claims or legal and regulatory proceedings could have a material, adverse effect on our results of operations, financial position or liquidity.

Health care companies are routinely subject to investigations by various governmental agencies. Under the federal False Claims Act (“FCA”), private parties have the right to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Certain of our individual facilities have received, and from time to time, other facilities may receive, government inquiries from, and may be subject to investigation by, federal and state agencies. Depending on whether the underlying conduct in these or future inquiries or investigations could be considered systemic, their resolution could have a material, adverse effect on our results of operations, financial position or liquidity.

Texas operates a state Medicaid program pursuant to a waiver from CMS under Section 1115 of the Social Security Act (the “Program”). The Program includes uncompensated-care pools; payments from these pools are intended to defray the uncompensated costs of services provided by our and other hospitals to Medicaid eligible or uninsured individuals. Separately, we and other hospitals provide charity care services in several communities in the state. In 2018, the Civil Division of the U.S. Department of Justice and the U.S. Attorney’s Office for the Southern District of Texas requested information about whether the Program, as operated in Harris County, complied with the laws and regulations applicable to provider related donations, and the Company cooperated with that request. On May 21, 2019, a qui tam lawsuit asserting violations of the FCA and the Texas Medicaid Fraud Prevention Act related to the Program, as operated in Harris County, was unsealed by the U.S. District Court for the Southern District of Texas. Both the federal and state governments declined to intervene in the qui tam lawsuit. The Company believes that our participation is and has been consistent with the requirements of the Program and is vigorously defending against the lawsuit being pursued by the relator. We cannot predict what effect, if any, the qui tam lawsuit could have on the Company.

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 9 — SHARE REPURCHASE TRANSACTIONS AND OTHER COMPREHENSIVE LOSS

During January 2023 and 2022, our Board of Directors authorized share repurchase programs for up to $3 billion and $8 billion, respectively, of our outstanding common stock. During the quarter ended March 31, 2023, we repurchased 3.340 million shares of our common stock at an average price of $253.26 per share through market purchases pursuant to the January 2022 authorization. At March 31, 2023, we had $3.740 billion of repurchase authorization available under the January 2022 and 2023 authorizations.

The components of accumulated other comprehensive loss are as follows (dollars in millions):

Unrealized Gains (Losses) on Available- for-Sale SecuritiesForeign Currency Translation AdjustmentsDefined Benefit PlansTotal
Balances at December 31, 2022$(30)$(373)$(87)$(490)
Unrealized gains on available-for-sale securities, net of $2 of income taxes55
Foreign currency translation adjustments, net of $3 of income taxes1515
Balances at March 31, 2023$(25)$(358)$(87)$(470)

NOTE 10 — SEGMENT AND GEOGRAPHIC INFORMATION

Effective January 1, 2023, we reorganized our operations from two geographically organized groups into three geographically organized groups: the National, American and Atlantic Groups. The National Group includes 57 hospitals located in Alaska, California, Idaho, Indiana, Kentucky, Nevada, New Hampshire, North Carolina, Tennessee, Utah and Virginia, the American Group includes 55 hospitals located in Colorado, central Kansas, Louisiana and Texas, and the Atlantic Group includes 61 hospitals located in Florida, Georgia, northern Kansas, Missouri and South Carolina. The seven hospitals we operate in England remain in the Corporate and other group. Prior periods presented have been restated according to the new organizational structure.

HCA HEALTHCARE, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

NOTE 10 — SEGMENT AND GEOGRAPHIC INFORMATION (continued)

Adjusted segment EBITDA is defined as income before depreciation and amortization, interest expense, gains and losses on sales of facilities, income taxes and net income attributable to noncontrolling interests. We use adjusted segment EBITDA as an analytical indicator for purposes of allocating resources to geographic areas and assessing their performance. Adjusted segment EBITDA is commonly used as an analytical indicator within the health care industry, and also serves as a measure of leverage capacity and debt service ability. Adjusted segment EBITDA should not be considered as a measure of financial performance under generally accepted accounting principles, and the items excluded from adjusted segment EBITDA are significant components in understanding and assessing financial performance. Because adjusted segment EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, adjusted segment EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. The geographic distributions of our revenues, equity in earnings of affiliates, adjusted segment EBITDA and depreciation and amortization for the quarters ended March 31, 2023 and 2022 and assets at March 31, 2023 and December 31, 2022 are summarized in the following table (dollars in millions):

20232022
Revenues:
National Group$4,616$4,202
Atlantic Group5,1094,686
American Group5,1995,206
Corporate and other667851
$15,591$14,945
Equity in losses (earnings) of affiliates:
National Group$**(**1)$—
Atlantic Group**(**1)—
American Group**(**12)(9)
Corporate and other32(2)
$18$(11)
Adjusted segment EBITDA:
National Group$1,149$955
Atlantic Group1,086850
American Group1,1331,316
Corporate and other**(**196)(177)
$3,172$2,944
Depreciation and amortization:
National Group$207$197
Atlantic Group239222
American Group237232
Corporate and other7381
$756$732
Adjusted segment EBITDA$3,172$2,944
Depreciation and amortization756732
Interest expense479408
Losses (gains) on sales of facilities15(10)
Income before income taxes$1,922$1,814
March 31, 2023December 31, 2022
Assets:
National Group$12,058$11,793
Atlantic Group15,38315,092
American Group17,74217,934
Corporate and other7,5287,619
$52,711$52,438

Next: Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF